![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
;
Could chemotherapy given both before and after surgery improve outcomes for patients with #GallbladderCancer (compared to chemo given only after surgery)? #ClinicalTrial EA2197/OPT-IN aims to find out. More info: https://bit.ly/EA2197 cc: @skmaithel @WinshipAtEmory
In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: http://bit.ly/ComboMATCH #PrecisionMedicine #ClinicalTrial
In phase 2 #ClinicalTrial EA1211/DIRECT, researchers are using an #imaging test called a FDG-PET/CT scan to try to better predict response to therapy for patients with #HER2positive #BreastCancer. Learn more: https://bit.ly/EA1211
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
41
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
